

AVOCOM-M

Mometasone Furoate 0.1% w/w, Miconazole Nitrate 2% w/w

THE **ENHANCED** TREATMENT

For **Vulvitis** Associated With
Vulvovaginal Candidiasis



 **Avalon** Pharma

AVOCOM-M

Mometasone Furoate 0.1% w/w, Miconazole Nitrate 2% w/w

THE **ENHANCED** TREATMENT
For **Vulvitis** Associated
with Vulvovaginal Candidiasis

- ◉ The enhanced treatment for vulvitis associated with vulvovaginal candidiasis
- ◉ Contains mometasone, effectively improves signs & symptoms of skin inflammation¹
- ◉ Contains miconazole, a highly effective treatment for skin fungal infections²
- ◉ Produced by Avalon Pharma, pioneering in derma-care

Dosage & administration:

Apply a thin film of **AVOCOM-M** cream to the affected skin areas once or twice daily.

AVOCOM-M

Mometasone Furoate 0.1% w/w, Miconazole Nitrate 2% w/w

Composition: Each gram of Avocom-M Cream contains 1 mg of Mometasone Furoate and 20 mg of Miconazole Nitrate in a suitable cream base. Properties: Avocom-M Cream contains Mometasone Furoate, which is a synthetic medium potency corticosteroid, has anti inflammatory, anti-pruritic and anti-allergic actions, Miconazole Nitrate, which is a broad-spectrum antifungal agent against pathogenic fungi, including yeasts and dermatophytes. Indications: Avocom-M Cream is indicated for mixed infections of the skin with the fungi. These include: atopic eczema, contact eczema, follicular eczema, infantile eczema, otitis external, anogenital pruritus (pruritis ani/vulvae), nummular eczema, post traumatic infective eczema, seborrheic or flexural eczema, neurodermatitis and psoriasis. Dosage & administration: Apply a thin film of Avocom-M Cream to the affected skin areas once or twice daily. Side Effects: Extended, recurrent applications may increase the risk of contact sensitization. Contraindication: Avocom-M Cream is contraindicated in patients who are hypersensitive to any ingredient in this preparation. Precautions:- For external use only. - Systemic absorption of topical corticosteroid will be increased, if extensive technique is used. Suitable precautions should be taken under these conditions or when long-term use is anticipated, particularly in infants and children. - Use of topical corticosteroid in children should be limited to the least amount compatible with an effective therapeutic regimen. - If irritation or sensitization develop with the use of Avocom-M Cream treatment should be discontinued. - Excessive or prolonged use of topical corticosteroid can suppress HPA axis, resulting in secondary adrenal insufficiency. Pregnancy & breast-feeding: - Since safe use of Mometasone Furoate 0.1% in pregnant women has not been established, topical corticosteroids should be used during pregnancy, only if the potential benefit Justifies potential risk to the fetus. - It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk; thus a decision should be made, whether to Discontinue nursing or to Discontinue the drug taking into account the importance of the drug to the mother. Storage conditions: Store below 30 OC. Shelf life after first opening is 30 days. Presentation: Avocom-M Cream is available in 30 g & 50 g aluminum tubes.



1. Faergemann J, Christensen O, Sjøvall P, Johnsson A, Hersle K, Nordin P, Edmar B, Svensson A, J Eur Acad Dermatol Venereol, 2000 Sep;14(5):393-6.
2. Alomar C, Bassas S, Casas M, Crespo V, Ferrándiz C, Fonseca E, Hernández B, Noguera J, Pedragosa R, Peyri J, et al. Arzneimittelforschung, 1992 May;42(5A):767-73.
Erratum in: Arzneimittelforschung 1992 Jun;42(6):884.



Middle East Pharmaceutical Industries Co. Ltd.
P.O. Box 301332 Riyadh 11372
Tel: +966 11 464 3924
Fax: +966 11 462 0471
Email: info@avalon.com.sa avalonpharmaceutical.com

AV-AMM-IB-04-01